LEXINGTON, Ky. (March 29, 2022) — The University of Kentucky Markey Cancer Foundation received a $1 million gift to create the world’s first distinguished professorship in neuroendocrine tumor (NET) research.
The Amanda W. Lockey Foundation gives the gift in support of UK Markey Cancer Center medical oncologist Lowell Anthony, M.D., a specialist in neuroendocrine tumor treatment. The distinguished professorship in NET research will support Anthony’s work by allowing him and his team to focus on clinical and translational research and the development of a radiotherapeutic program.
“This generous gift is recognition of our expertise in neuroendocrine tumors and will allow the center to advance our understanding of NET biology,” said Anthony. “The NET professorship provides additional resources to support our growth in translational NET research and making Markey cutting edge with this technology.”
The professorship will support his team’s work on the UK College of Medicine and Markey Cancer Center’s Radiopharmaceutical Therapy Alliance (RPTA) that supports transdisciplinary collaborations related to radiation medicine science and clinical investigations, specifically through the Radiopharmaceutical Therapy Program (RPT). Anthony says this gift and his team’s efforts will make the UK Markey Cancer Center one of the elite RPT programs in the country.
Anthony was among the first oncologists to run clinical trials with RPT dating back to 1995. The revolutionary treatments being developed and tested by Anthony and his colleagues have been central in extending both the duration and quality of life in patients with neuroendocrine tumors, which can develop anywhere endocrine cells are present.
“My work in RPT began with a patient nearly three decades ago and since then, we have made tremendous strides in making these therapies available to our patients,” Anthony said. “Since joining Markey and Dr. Mark Evers’ team in 2011, we have three active RPT clinical trials and three more in development. In fact, we have the most NET RPT clinical trials open at a single center in the United States.”
The gift is the largest given to the Markey Cancer Foundation from the Amanda W. Lockey Foundation in the last three years and comes as part of a campaign in support of the Markey Cancer Center’s application for obtaining National Cancer Institute (NCI) Comprehensive Cancer Center status. This is the highest level of recognition a cancer center can receive.
A distinguished professorship is an endowed position, wherein the donated money is permanently invested and generates annual spending distributions in order to build permanent and sustainable funding, which is then used to support the goals and objectives of its named role. Endowed positions are highly coveted achievements and play a central role in retaining and attracting the highest level clinician-scientists and researchers.
“The UK Markey Cancer Center was so fortunate to obtain such a high-level recruit in Dr. Anthony from LSU,” said Michael Delzotti, Markey Cancer Foundation president & CEO. “He is an internationally recognized NET researcher and physician-scientist. This generous philanthropic support by the Lockey Foundation will further accelerate the life-saving and cutting-edge research he is doing at Markey.”
To learn more about NET research being done at the Markey Cancer Center or for ways in which you can support the Markey Cancer Center’s drive for NCI Comprehensive status, please contact the Markey Cancer Foundation at HelpBeatCancer@uky.edu.
University of Kentucky Markey Cancer Foundation
The University of Kentucky Markey Cancer Foundation has been recognized as a forerunner in championing cancer research in Kentucky through direct support of the Markey Cancer Center, Kentucky’s only National Cancer Institute (NCI)-designated cancer center. In addition to the Foundation’s support in funding innovative research, early detection and prevention initiatives, the Foundation is working to help the Markey Cancer Center achieve its goal of being named a National Cancer Institute Comprehensive Cancer Center, the highest designation a cancer center can receive.
The University of Kentucky is increasingly the first choice for students, faculty and staff to pursue their passions and their professional goals. In the last two years, Forbes has named UK among the best employers for diversity, and INSIGHT into Diversity recognized us as a Diversity Champion four years running. UK is ranked among the top 30 campuses in the nation for LGBTQ* inclusion and safety. UK has been judged a “Great College to Work for" three years in a row, and UK is among only 22 universities in the country on Forbes' list of "America's Best Employers." We are ranked among the top 10 percent of public institutions for research expenditures — a tangible symbol of our breadth and depth as a university focused on discovery that changes lives and communities. And our patients know and appreciate the fact that UK HealthCare has been named the state’s top hospital for five straight years. Accolades and honors are great. But they are more important for what they represent: the idea that creating a community of belonging and commitment to excellence is how we honor our mission to be not simply the University of Kentucky, but the University for Kentucky.